A Nature paper reports the first direct small-molecule targeting of microphthalmia-associated transcription factor (MITF), the melanoma oncogene long classified as undruggable.

Titled "Fragment-based discovery enables direct targeting of the melanoma oncogene MITF," the study applies fragment-based drug discovery — a method that screens low-molecular-weight chemical starting points and grows them into drug-like compounds — to a transcription factor. That class of protein has historically resisted direct chemical inhibition, the authors note.

What did the paper show?

The Nature report describes a fragment-based screening campaign that identified compounds engaging MITF directly, followed by iterative medicinal chemistry that improved binding affinity and selectivity. The authors frame the work as the first direct chemical probe for the MITF oncogene.

The paper stops at the chemical-biology stage. No animal efficacy data and no human trial results appear in the report; the work presents as a starting point for drug discovery against MITF-dependent melanoma.

Why is MITF a hard target?

MITF is a lineage-defining transcription factor for melanocytes and an oncogene in cutaneous melanoma, the source states. As a transcription factor, it operates inside the nucleus by binding DNA and regulating other genes, a mechanism that gives chemists less to work with than the deep pockets of enzymes or the well-defined surfaces of cell-surface receptors. That structural problem is the textbook reason transcription factors carry the "undruggable" label.

Melanoma drug development has worked around MITF by targeting upstream signaling — most prominently BRAF V600E inhibitors and MEK inhibitors — and by harnessing the immune system through checkpoint blockade. A direct MITF compound would address melanomas that escape those routes.

How does fragment-based discovery differ here?

Fragment-based drug discovery screens small chemical fragments — typically well under the size of a conventional drug lead — against a purified protein and reads binding with biophysical methods. The approach samples chemical space efficiently and can find starting points in shallow or unusual pockets that larger libraries miss. The Nature team applied that workflow to MITF, identified initial binders, and used structural biology to guide the design of more potent analogues.

The result, the authors say, is a tool compound researchers can use to study MITF in cells and a potential starting point for an oral targeted therapy in melanoma.

What comes next for melanoma drug development?

The next milestones sit in preclinical work: pharmacokinetics, target engagement in cell lines and mouse models, and selectivity against related transcription factors. If the chemistry holds, IND-enabling studies and a first-in-human trial in MITF-amplified or MITF-dependent melanoma would follow, with researchers watching for activity in tumors that escape BRAF and MEK inhibition.

By Tom Whitfield, Derm Field